[go: up one dir, main page]

AR092873A1 - PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS - Google Patents

PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS

Info

Publication number
AR092873A1
AR092873A1 ARP130103464A ARP130103464A AR092873A1 AR 092873 A1 AR092873 A1 AR 092873A1 AR P130103464 A ARP130103464 A AR P130103464A AR P130103464 A ARP130103464 A AR P130103464A AR 092873 A1 AR092873 A1 AR 092873A1
Authority
AR
Argentina
Prior art keywords
peptides
glp
gip
receptors
glucagon
Prior art date
Application number
ARP130103464A
Other languages
Spanish (es)
Inventor
Bahekar Rajesh
C Desai Tanjit
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR092873A1 publication Critical patent/AR092873A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Péptidos, que tienen la fórmula estructural (1) y muestran actividad agonista triple de los receptores de GIP (polipéptido inhibidor gástrico), GLP-1 (péptido similar a glucagón) y glucagón. Estos péptidos exhiben estabilidad incrementada a la escisión proteolítica; en especial, contra la enzima DPP-IV (Dipeptidil Peptidasa-lV). Estos péptidos pueden ser suministrados por vías de administración parenterales, para el tratamiento o la prevención de diabetes, obesidad y trastornos metabólicos relacionados. Péptidos como agonistas triples de los receptores de GIP, GLP-1 y glucagón, que tienen la siguiente estructura de fórmula (1): A-Z¹-Z²-Z³-Z⁴-Z⁵-Z⁶-Z⁷-Z⁸-Z⁹-Z¹⁰-Z¹¹-Z¹²-Z¹³-Z¹⁴-Z¹⁵-Z¹⁶-Z¹⁷-Z¹⁸-Z¹⁹-Z²⁰-Z²¹-Z²²-Z²³-Z²⁴-Z²⁵-Z²⁶-Z²⁷-Z²⁸-Z²⁹-B (1). Composición farmacéutica.Peptides, which have the structural formula (1) and show triple agonist activity of GIP receptors (gastric inhibitor polypeptide), GLP-1 (glucagon-like peptide) and glucagon. These peptides exhibit increased stability to proteolytic cleavage; especially against the DPP-IV enzyme (Dipeptidyl Peptidase-lV). These peptides can be supplied by parenteral routes of administration, for the treatment or prevention of diabetes, obesity and related metabolic disorders. Peptides as triple agonists of the GIP, GLP-1 and glucagon receptors, which have the following structure of formula (1): A-Z¹-Z²-Z³-Z⁴-Z⁵-Z⁶-Z⁷-Z⁸-Z⁹-Z¹⁰-Z¹¹ -Z¹²-Z¹³-Z¹⁴-Z¹⁵-Z¹⁶-Z¹⁷-Z¹⁸-Z¹⁹-Z²⁰-Z²¹-Z²²-Z²³-Z²⁴-Z²⁵-Z²⁶-Z²⁷-Z²⁸-Z²⁹-B (1). Pharmaceutical composition

ARP130103464A 2012-09-26 2013-09-26 PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS AR092873A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2807MU2012 2012-09-26

Publications (1)

Publication Number Publication Date
AR092873A1 true AR092873A1 (en) 2015-05-06

Family

ID=49918772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103464A AR092873A1 (en) 2012-09-26 2013-09-26 PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS

Country Status (2)

Country Link
AR (1) AR092873A1 (en)
WO (1) WO2014049610A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838503C (en) 2011-06-10 2020-02-18 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
ES2710356T3 (en) 2011-06-17 2019-04-24 Hanmi Science Co Ltd A conjugate comprising oxintomodulin and an immunoglobulin fragment, and use thereof
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
MY197849A (en) 2012-11-06 2023-07-20 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2015086686A2 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
MA43289B1 (en) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Long-acting insulin and associated use
AR100639A1 (en) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
TWI684458B (en) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
TWI802396B (en) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
KR102418477B1 (en) * 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
AR103322A1 (en) 2014-12-30 2017-05-03 Hanmi Pharm Ind Co Ltd GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TWI726889B (en) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 Protease-resistant lipidated peptides
PT3322437T (en) 2015-06-30 2024-03-20 Hanmi Pharmaceutical Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
UY36870A (en) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd NEW INSULIN ANALOGS
EA038544B1 (en) * 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Triple glucagon/glp-1/gip receptor agonist
DK3464336T3 (en) 2016-06-01 2022-05-09 Athira Pharma Inc CONNECTIONS
UA126662C2 (en) 2016-06-29 2023-01-11 Ханмі Фарм. Ко., Лтд. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereofgj[slyt uk.
BR112019005637A2 (en) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd insulin analogues with reduced affinity for the insulin receptor and its use
TW201833131A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 New compounds as peptidic glp1/glucagon/gip receptor agonists
TW201833132A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
TWI798209B (en) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 A conjugate of insulin analog with reduced affinity to insulin receptor and use thereof
CN120887972A (en) * 2017-11-24 2025-11-04 浙江道尔生物科技有限公司 A glucagon analogue for treating metabolic diseases
TWI744579B (en) 2017-12-21 2021-11-01 美商美國禮來大藥廠 Incretin analogs and uses thereof
TWI810937B (en) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 Incretin analogs and uses thereof
AU2019250362B2 (en) 2018-04-10 2025-11-06 Sanofi-Aventis Deutschland Gmbh Lixisenatide synthesis with capping
JP7434169B2 (en) 2018-04-10 2024-02-20 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Method for cleaving solid phase-bound peptides from solid phase
TW202015735A (en) 2018-05-30 2020-05-01 法商賽諾菲公司 Conjugates comprising an glp-1/glucagon/gip triple receptor agonist, a linker and hyaluronic acid
TW202523681A (en) * 2018-07-23 2025-06-16 美商美國禮來大藥廠 Gip/glp1 co-agonist compounds
AU2020334993B2 (en) 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
TWI795698B (en) 2019-12-18 2023-03-11 美商美國禮來大藥廠 Incretin analogs and uses thereof
TW202247856A (en) * 2020-12-24 2022-12-16 南韓商韓美藥品股份有限公司 Novel trigonal glucagon/glp-1/gip receptor agonist and use thereof
CA3257100A1 (en) * 2022-05-27 2023-11-30 D&D Pharmatech Inc. Peptide compositions and methods of use thereof
AU2024215381A1 (en) 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
CN121285571A (en) 2023-06-09 2026-01-06 太阳医药工业有限公司 GLP-1/GIP dual, GLP-1/GCG dual and GLP-1/GIP/GCG triple receptor agonists
GB202316884D0 (en) * 2023-11-03 2023-12-20 Constructive Biology Ltd Glucagon-like peptide 1 agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795562A4 (en) 1994-11-07 2000-08-09 Kyowa Hakko Kogyo Kk NEW OXYNTOMODULINE
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2008543816A (en) 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド Novel compounds and their effects on eating behavior
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
ES2382579T3 (en) * 2007-12-11 2012-06-11 Cadila Healthcare Limited Peptidomimetics with glucagon antagonist activity and GLP-1 agonist
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
MX337038B (en) 2008-06-17 2016-02-10 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
MX2011006320A (en) 2008-12-15 2011-09-22 Zealand Pharma As Glucagon analogues.
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
KR20110126592A (en) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 Glucagon analogues
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US20120264685A1 (en) * 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
AU2011206979B2 (en) * 2010-01-20 2015-09-10 Zealand Pharma A/S Treatment of cardiac conditions
ES2634716T3 (en) 2011-05-31 2017-09-28 Celgene International Ii Sàrl New stabilizers and modulators of the GLP-1 receptor
CA2838503C (en) 2011-06-10 2020-02-18 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
ES2710356T3 (en) 2011-06-17 2019-04-24 Hanmi Science Co Ltd A conjugate comprising oxintomodulin and an immunoglobulin fragment, and use thereof

Also Published As

Publication number Publication date
WO2014049610A3 (en) 2014-10-02
WO2014049610A2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
AR092873A1 (en) PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS
CY1121423T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A METABOLIC SYNDROME
CL2012002356A1 (en) Heterocyclic acid compounds derived from bisyl-linked aryltriazolones, vasopressin receptor inhibitors v1a and v2; preparation procedure; pharmaceutical composition; and its use to treat and / or prevent acute and chronic heart failure, hyponatremia, among others.
MX382408B (en) GLUCAGON AND GLP-1 RECEPTOR COAGONISTS.
BRPI0924307A8 (en) OXINTOMODULIN ANALOGS
PE20160683A1 (en) ACCURATE GLUCAGON ANALOGS
GT201200144A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A GLP-1 AGONIST, AN INSULIN AND METIONIN
CO2019005924A2 (en) Dual acylated agonists of glp-1 / glp-2
UA114710C2 (en) OXYNTOMODULIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OBESITY CONTAINED
CO6660483A2 (en) Glucagon analogues
MX2019008148A (en) USE OF LONG-ACTING GLP-1 PEPTIDES.
AR069136A1 (en) COMPOUNDS THAT DISPLAY ANTIGONIST ACTIVITY OF GLUCAGON AND AGONIST OF GLP-1 (PEPTIDE SOMILAR TO GLUCAGON TYPE 1) AND USES OF THE SAME
PE20180449A1 (en) DERIVATIVE OF GLUCAGON AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME
PE20151239A1 (en) DERIVATIVES OF EXENDIN-4 FUNCTIONALIZED
CL2012003211A1 (en) Compounds derived from piperidinyl substituted lactams, modulators of gpr119; process to prepare the compounds; pharmaceutical composition comprising the compounds; and use of the compounds in the preparation of medicaments for the treatment or prevention of type 2 diabetes, obesity and related conditions
CL2012003053A1 (en) Pharmaceutical combination comprising a glp-1 receptor agonist and linagliptin, dpp-4 inhibitor; use of the pharmaceutical combination for the treatment of type 2 diabetes and obesity.
AR087973A1 (en) VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
MX375731B (en) 1,4-DISUBSTITUTED PYRIDAZINE ANALOGUES AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO SMN DEFICIENCY.
PE20142113A1 (en) GLUCAGON ANALOGS
AR092589A1 (en) GLUCAGON ANALOGS
MX369259B (en) ORAL DOSAGE OF PEPTIDE COMPOUNDS SIMILAR TO GLAUCON-1 (GLP-1).
CR11849A (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
MX383686B (en) 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CONDITIONS RELATED TO SMN DEFICIENCY.
HN2012000031A (en) COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
PE20171622A1 (en) INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure